Centessa Pharma up after Leerink raises price target

Centessa Pharmaceuticals

14/03/2025 16:08

** U.S.-listed shares of Centessa Pharmaceuticals 260y.F, CNTA.O rise 3.5% to $17.45

** Brokerage Leerink raises PT to $36 from $24, reiterates "outperform" rating

** CNTA shares offer tremendous upside potential because its orexin portfolio is targeting mega-blockbuster hypersomnia and excessive daytime sleepiness markets - brokerage

** Centessa has disclosed potency and selectivity for the orexin 2 receptor which appear to be "best-in-class" - Leerink

** Orexin receptor 2 is a protein in the brain that helps control sleep and wakefulness

** All nine brokerages, covering Centessa, rate the stock "buy" or higher; their median PT is $27, according to data compiled by LSEG

** CNTA more than doubled last year

 (Reporting by Juby Babu in Mexico City)

 ((Juby.Babu@thomsonreuters.com;))